Publicaciones en colaboración con investigadores/as de University of Chicago (6)

2021

  1. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  2. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621

2020

  1. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Cancer Cell, Vol. 38, Núm. 4, pp. 500-515.e3

2017

  1. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

    Cell, Vol. 171, Núm. 4, pp. 934-949.e15

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

  2. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

    Clinical Cancer Research